Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 6, 2024PharmaceuticalsOpen Access

Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJiafeng ZhangBSBao‐Chang SunZSZ. Sheng

Discussion

Loading...

Member takes

Overview

Cross-sectional study reveals a 6.5% pre-treatment drug resistance rate in newly diagnosed HIV patients, indicating the need for non-NNRTI initial therapies.

Key Points

  • Pre-treatment drug resistance reached 6.5% among newly diagnosed individuals, driven largely by resistance to non-nucleoside reverse transcriptase inhibitors at 4.1%.
  • Cross-sectional investigation of 473 treatment-naive individuals utilized nested PCR and genomic sequencing to detect drug resistance mutations across two viral gene regions.
  • Supports adopting non-NNRTI regimens and expanding pre-treatment genotypic testing before initiating anti-retroviral therapy to prevent early clinical treatment failure.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e6129eb6db6435875a5a10https://doi.org/10.3390/ph17070900
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Characterization of Pretreatment Drug Resistance among people living with HIV from 2018 to 2022 in Guangzhou, China2024
  2. 2Exploring disparities in HIV-1 pretreatment and acquired drug resistance in China from 2003 to 20222024
  3. 3Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China2024 · 6 citations
  4. 4Molecular epidemiology and pretreatment drug resistance of HIV-1 among newly diagnosed individuals in Nanning City, Guangxi, China.2025 · 3 citations
  5. 5Characteristics of drug resistance mutations in ART-experienced HIV-1 patients with low-level viremia in Zhengzhou City, China2024 · 18 citations